Results 81 to 90 of about 53,590 (235)
Daunorubicin in acute leukaemia [PDF]
Postgraduate Medical Journal, 1970 Summary Daunorubicin has been used in the treatment of six cases of acute lymphoblastic and thirteen cases of acute myeloblastic and mono-myeloblastic leukaemia. Complete remissions were obtained in eight patients, three with acute lymphoblastic leukaemia and five with acute myeloblastic leukaemia.
R L, Souhami, T A, Prankerd
openaire +2 more sources
British Journal of Haematology, EarlyView.Summary Mixed phenotype acute leukaemia (MPAL) is a rare subtype of acute leukaemia possessing significant therapeutic challenges, as no standardized, evidence‐based treatment regimen has been defined. In this nationwide study, we aimed to assess the effect of an acute lymphoid leukaemia (ALL)‐like regimen; an acute myeloid leukaemia (AML)‐like regimen;
Lisa‐Maj Christensen +11 more
wiley +1 more source
Preclinical Evaluation of Ureidosulfamate Carbonic Anhydrase IX/XII Inhibitors in the Treatment of Cancers [PDF]
, 2019 Carbonic anhydrases (CAs) are a family of enzymes involved in the pH regulation of metabolically active cells/tissues. Upregulation of the CAIX/XII isoforms is associated with hypoxic tumours and clinically linked with malignant progression, treatment ...
Gieling, Roben, Williams, Kaye J.
core +2 more sources
British Journal of Pharmacology, EarlyView.Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski +13 more
wiley +1 more source
The anticancer agent prodigiosin is not a multidrug resistance protein substrate [PDF]
, 2013 The brilliant red pigments prodiginines are natural secondary metabolites that are produced by select species of Gram-negative and Gram-positive bacteria.
Dinmohammadi, F. +5 more
core +1 more source
Cancer Science, EarlyView.Daunorubicin dose escalation from 45 to 60 mg/m2 provides no clinical benefit for AML patients aged 55–65. A dose of 45 mg/m2 should remain the preferred regimen for this population. ABSTRACT Daunorubicin dose optimization remains crucial for AML treatment.
Chunlin Zhou +15 more
wiley +1 more source
DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA
Mediterranean Journal of Hematology and Infectious Diseases, 2019 BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remission ...
Juan Eduardo Megias-Vericat +26 more
doaj +1 more source
Frontiers in Chemistry, 2020 Measuring the concentration of anticancer drugs in pharmacological and biological samples is a very useful solution to investigate the effectiveness of these drugs in the chemotherapy process.
Marzieh Alizadeh +4 more
doaj +1 more source
Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy [PDF]
, 2015 The selective and efficient drug delivery to tumor cells can remarkably improve different cancer therapeutic approaches. There are several nanoparticles (NPs) which can act as a potent drug carrier for cancer therapy.
Bahrami, B. +8 more
core +1 more source
Cell Proliferation, EarlyView.We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang +12 more
wiley +1 more source